Findings from a phase 3 trial with Blenrep, Velcade and dexamethasone in relapsed/refractory multiple myeloma will be ...
Patient dosing has begun in a phase 1 trial evaluating QXL138AM, a masked immunocytokine targeting CD138, in advanced solid ...
During a Case-Based Roundtable® event, Saad Z. Usmani, MD, FACP, MBA, discussed quality of life and the future with CAR ...
News Medical on MSN3d
Scientists create an scRNA-seq atlas of the multiple myeloma immune microenvironment across disease stagesMultiple myeloma (MM) is an incurable blood cancer, leading to weakened immunity, bone damage, and other serious health ...
GlobalData on MSN3d
EMA’s CHMP recommends Sanofi’s Sarclisa approval for multiple myelomaThe European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of ...
clinicaltrialsarena on MSN3d
GSK reports positive outcomes from Phase III multiple myeloma treatment trialGSK has announced positive headline outcomes from a Phase III trial of Blenrep with bortezomib and dexamethasone for multiple ...
GSK is carving out a niche for Blenrep in the second-line multiple myeloma setting, for which it projects multi-blockbuster ...
Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced abstracts detailing selinexor data have been selected to be ...
The department used its new system for determining whether a condition is service-connected to give affected veterans access ...
GSK’s 3 billion pounds sterling peak sales goal for its multiple myeloma drug Blenrep appears increasingly attainable thanks ...
GSK's drive to resurrect its multiple myeloma therapy Blenrep has continued with new data from the DREAMM-7 trial showing an increase in overall survival (OS) with the drug had reached statistical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback